Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
salmonella-based chlamydia vaccine
- Development stage
- Preclinical
- Lead developer
- Prokarium
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral, Mucosal
01
Overview
A **salmonella-based chlamydia vaccine** is a preclinical live bacterial vector vaccine concept rather than a single clearly identified clinical product. Published patent and grant materials describe **attenuated Salmonella enterica vectors**, including strains with **aroC** and **ssaV** attenuating mutations, engineered to carry heterologous nucleic acids encoding **immunogenic Chlamydia peptides or antigens** for prevention of *Chlamydia trachomatis* infection. The intended mechanism is mucosal and systemic immunization through oral or other mucosal delivery of the live attenuated Salmonella carrier, which infects antigen-presenting cells and drives **Th1-skewed cellular and humoral immune responses** against chlamydial antigens. No distinct approved brand, generic, or clinical-stage product name could be confirmed for this exact term, so it is best treated as a nonspecific vaccine platform description rather than a unique pharmaceutical asset.
- Other names
- salmonella vectored vaccines against chlamydiasalmonella-based vaccine against chlamydia trachomatis
02
Targets
OmpA (Outer membrane protein A)
Beyond the preview
Go deeper on salmonella-based chlamydia vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on salmonella-based chlamydia vaccine.